The subcutaneous vaccine failed to induce S-specific IgA in the nasal, but strongly elicited S-specific IgG in the nasal mucosa, suggesting that S-specific IgG in the nasal mucosa likely contributes partially to prevent upper respiratory tract infection. This evidence concerns the gene CD79A and Recurrent upper respiratory tract infections.